Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Injury Clear all
Completed Phase 2Phase 3 Interventional Results available

Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure

NCT04311697
View directory record Official record
Conditions
Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Corona Virus Infection, Acute Lung Injury
Interventions
Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care
Drug
Lead sponsor
APR Applied Pharma Research s.a.
Other
Eligibility
18 Years to 100 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Fullerton, California • Irvine, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Jun 10, 2026, 11:21 PM EDT
Completed No phase listed Observational

Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn

NCT02653157
View directory record Official record
Conditions
Multi-drug Resistant Gram-negative Bacilli Colonization
Interventions
MDR-GNB
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 10, 2026, 11:21 PM EDT
Terminated Phase 2 Interventional Results available

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

NCT02370095
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Treprostinil Inhalation Solution, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jun 10, 2026, 11:21 PM EDT
Withdrawn Phase 1 Interventional

A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure

NCT04574869
View directory record Official record
Conditions
Acute Lung Injury, ALI, COVID-19
Interventions
RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
Drug
Lead sponsor
ReAlta Life Sciences, Inc.
Industry
Eligibility
18 Years to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Jun 10, 2026, 11:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

NCT04351243
View directory record Official record
Conditions
COVID-19
Interventions
Gimsilumab, Placebo
Drug
Lead sponsor
Kinevant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Jun 10, 2026, 11:21 PM EDT
Terminated Phase 3 Interventional

Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation

NCT00060450
View directory record Official record
Conditions
Ischemia-Reperfusion Injury
Interventions
nitric oxide for inhalation, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jun 10, 2026, 11:21 PM EDT
Completed Not applicable Interventional Results available

Non-invasive Vagal Neurostimulation (nVNS) for Traumatic Brain Injury (TBI)-Induced Acute Respiratory Distress

NCT04935697
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Traumatic Brain Injury
Interventions
nVNS, SOC
Device · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
12 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Completed No phase listed Observational

Social Determinants of Health in Patients With Penetrating Trauma Injuries Before and During the COVID-19 Pandemic

NCT06135610
View directory record Official record
Conditions
Penetrating Injury, COVID-19, Social Determinants of Health
Interventions
Postive SAR-CoV-2 PCR nasopharyngeal swab
Diagnostic Test
Lead sponsor
Kern Medical Center
Other
Eligibility
Not listed
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bakersfield, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jun 10, 2026, 11:21 PM EDT
Approved For Marketing No phase listed Expanded access

Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer

NCT06064500
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
U.S. locations
9
States / cities
New Haven, Connecticut • Miami Beach, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jun 10, 2026, 11:21 PM EDT
Completed No phase listed Observational

Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury

NCT00605527
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Days to 18 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
5
States / cities
Fresno, California • Los Angeles, California • Oakland, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2020 · Synced Jun 10, 2026, 11:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Professional Peer Resilience Initiative

NCT04396600
View directory record Official record
Conditions
Stress, Stress Disorder, Stress, Psychological, Trauma, Psychological, Anxiety, Anxiety State, Post Traumatic Stress Disorder, Secondary Traumatic Stress, Professional Quality of Life, Stress Related Disorder, Stress Reaction, Stress Risk, Mental Resilience, Emotional Resilience
Interventions
MinnRAP Peer Support Program
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jun 10, 2026, 11:21 PM EDT
Completed No phase listed Observational

Phase II Evaluation of Exhaled Nitric Oxide (NO)

NCT01392144
View directory record Official record
Conditions
Lung Cancer
Interventions
Nitric oxide breath test, Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jun 10, 2026, 11:21 PM EDT
Withdrawn Not applicable Interventional

Paradoxical Response to Chest Wall Loading in Mechanically Ventilated Patients

NCT06093958
View directory record Official record
Conditions
ARDS, COVID-19, Mechanical Ventilation Pressure High, Ventilator-Induced Lung Injury
Interventions
Manual loading of the chest wall
Diagnostic Test
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 10, 2026, 11:21 PM EDT
Terminated Not applicable Interventional Results available

Orthosis of Acute Traumatic Rib Fractures Via RibFx Belt for Pain Alleviation and Improved Pulmonary Function

NCT03846024
View directory record Official record
Conditions
Rib Fracture, Rib Fracture Multiple, Trauma, Trauma Chest, Trauma Injury, Trauma, Multiple
Interventions
RibFx Orthosis Belt
Device
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jun 10, 2026, 11:21 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

NCT06853223
View directory record Official record
Conditions
Primary Graft Dysfunction, Lung Transplantation, Acute Lung Injury(ALI), Natural Killer Cell Mediated Immunity
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Withdrawn Phase 2 Interventional

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

NCT00793013
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
Interventions
Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode
Device
Lead sponsor
University of Tennessee, Chattanooga
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jun 10, 2026, 11:21 PM EDT
Completed Not applicable Interventional Results available

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204
View directory record Official record
Conditions
Lung Diseases, Medication Compliance
Interventions
Fluticasone propionate 230mcg for 3 Months, Current Treatment or no treatment, Salmeterol 21mcg for 3 Months
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 10, 2026, 11:21 PM EDT
Active, not recruiting No phase listed Observational

A Cohort Study of the Intestinal Microbiota of Premature Infants

NCT03717584
View directory record Official record
Conditions
Necrotizing Enterocolitis, Bronchopulmonary Dysplasia, Growth Failure
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 33 Weeks
Enrollment
300 participants
Timeline
2018 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Active, not recruiting No phase listed Observational

Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy

NCT05717998
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, GastroEsophageal Cancer, Esophagus Cancer
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging of the Heart, Positron Emission Tomography
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Completed Phase 2Phase 3 Interventional

Vitamin D Supplementation for Extremely Preterm Infants

NCT01600430
View directory record Official record
Conditions
Vitamin D Deficiency, Preterm Infants, Bronchopulmonary Dysplasia
Interventions
Cholecalciferol, Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Minute to 7 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 10, 2026, 11:21 PM EDT
Not listed Not applicable Interventional

Biomarkers, Genomics, Physiology in Critically Ill and ECMO Patients

NCT04669444
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Cardiac Failure, Extracorporeal Membrane Oxygenation Complication, Respiratory Failure, Renal Failure, Critical Illness, Pulmonary Disease
Interventions
Ventilator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jun 10, 2026, 11:21 PM EDT
Recruiting Phase 2 Interventional

Lipid Infusions to Optimize Nutrition Trial

NCT06915441
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Neurodevelopmental Impairment
Interventions
SOLE, MOLE
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
12 Hours to 28 Weeks
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Recruiting No phase listed Observational

Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.

NCT07125079
View directory record Official record
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jun 10, 2026, 11:21 PM EDT
Terminated Phase 1 Interventional

Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

NCT04526912
View directory record Official record
Conditions
Acute Lung Injury
Interventions
VIB7734, Placebo
Drug
Lead sponsor
Viela Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jun 10, 2026, 11:21 PM EDT